Introduction:

Infliximab is a drug, a monoclonal antibody with a potent anti-inflammatory action. Its mechanism of action decreases the effect of tumor necrosis factor, on the other hand, it induces apoptosis (cell death) of abnormally activated lymphocytes. It is one of the so-called biological treatments, developed for the treatment of various diseases, including Crohn's disease which is characterized by segmental granulomatous inflammation of the intestinal tract and usually affects the skin tissues.

Case report:

42-year-old white race male with a history of treatment since 2006, he underwent different treatments with few results. A new therapeutic behavior is taken in 2018 with the monoclonal antibody Infliximab.

Conclusions:

results with the new therapy were satisfactory.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )